Marshall Wace
ALLO icon

Marshall Wace’s Allogene Therapeutics ALLO Stock Holding History

Marshall Wace’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.6M Buy
5,095,408
+1,647,424
+48% +$3.62M 0.01% 1015
2026
Q1 		$8.41M Buy
3,447,984
+3,162,423
+1,107% +$6.34M 0.01% 1058
2025
Q4 		$391K Buy
+285,561
New +$377K ﹤0.01% 2349
2023
Q4 		– Sell
-228,642
Closed -$725K – 2135
2023
Q3 		$725K Buy
228,642
+185,296
+427% +$812K ﹤0.01% 1599
2023
Q2 		$215K Sell
43,346
-391,674
-90% -$2.12M ﹤0.01% 2230
2023
Q1 		$2.15M Buy
+435,020
New +$2.79M ﹤0.01% 1419
2022
Q4 		– Sell
-12,593
Closed -$136K – 2897
2022
Q3 		$136K Buy
+12,593
New +$171K ﹤0.01% 3147
2022
Q1 		– Sell
-948,624
Closed -$14.2M – 3301
2021
Q4 		$14.2M Buy
+948,624
New +$16.7M 0.03% 643
2021
Q3 		– Sell
-456,591
Closed -$11.9M – 2977
2021
Q2 		$11.9M Buy
+456,591
New +$13M 0.05% 403
2020
Q2 		– Sell
-132,006
Closed -$2.57M – 1509
2020
Q1 		$2.57M Sell
132,006
-21,099
-14% -$503K 0.03% 546
2019
Q4 		$3.98M Buy
+153,105
New +$4.22M 0.03% 606
2019
Q3 		– Sell
-19,524
Closed -$525K – 1651
2019
Q2 		$525K Sell
19,524
-42,118
-68% -$1.17M ﹤0.01% 1072
2019
Q1 		$1.78M Buy
+61,642
New +$1.79M 0.02% 778

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Marshall Wace's ALLO Position: Q2 2026 in Review

Marshall Wace increased its Allogene Therapeutics (ALLO) stake by 48% in Q2 2026, buying an estimated $3.62M and bringing the position to 5,095,408 shares worth $10.6M. The position accounts for 0.01% of the portfolio, ranked #1015.

Marshall Wace first reported a position in ALLO in Q1 2019 and has held it in 13 quarters since. The position peaked at $14.2M in Q4 2021. 210 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Marshall Wace held 5,095,408 shares of Allogene Therapeutics worth $10.6M as of Q2 2026.
  • Marshall Wace bought 1,647,424 Allogene Therapeutics shares in Q2 2026, an estimated $3.62M.
  • Allogene Therapeutics made up 0.01% of Marshall Wace's portfolio in Q2 2026, its #1015 holding.
  • Marshall Wace first reported a position in Allogene Therapeutics in Q1 2019 and has held it in 13 quarters since.
  • Marshall Wace's Allogene Therapeutics position peaked at $14.2M in Q4 2021.
  • 210 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.